Investors
OMX Stockholm
Upcoming events
Half-year Report January-June 2024
H.C. Wainwright 26th Annual Global Investment Conference, New York
Interim Report for January-September 2024
Press releases
Our latest press releases
Regulatory press release
18/07/2024
03/07/2024
Regulatory press release
28/06/2024
Regulatory press release
27/06/2024
Hansa Biopharma in brief
We are a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
Upcoming
Key progress and look ahead
Progress to date | What’s next 2H ’24 | Looking ahead - 2025 | |
|---|---|---|---|
| EARLY DEVELEOPMENT | COMPLETED NICE-01 Ph 1 safety/tolerability for HNSA-5487 | HNSA-5487 Ph 1 data on exploratory endpoints and clinical development path | HNSA-5487 clinical development |
| TRANSPLANTATION | FULL RANDOMIZATION ConfIdeS Ph 3 trial | 15-HMedIdeS-14 data publication in peer reviewed journal | ConfIdeS Ph 3 12 month follow up and BLA submission in 2H Post Approval Efficacy Study readout |
| GENE THERAPY | STUDY INITIATED: SRP 9001-104 Ph 1 study (DMD) Genethon (Crigler-Najjar) preclinical AskBio (Pompe) preclinical | Genethon trial initiated (Crigler-Najjar) | SRP 9001-104 Ph 1 study (DMD) initial data readout |
| AUTOIMMUNE | TRIAL COMPLETED 15-MedIdeS-09 (GBS) Ph 2 trial 70% ENROLLED GOOD-IDES-12 Ph 3 (anti-GBM) trial | 15-MedIdeS-09 Ph 2 (GBS) 16-MedIdeS-12 Ph 2 (AMR) | GOOD-IDES-12 Ph 3 (anti-GBM) |
